PMID: 11316545Apr 24, 2001Paper

Hyperfractionated chemoradiation with carbogen breathing, with or without erythropoietin: a stepwise developed treatment schedule for advanced head-and-neck cancer

International Journal of Radiation Oncology, Biology, Physics
J C MartinezJ A Saavedra

Abstract

To investigate the influence of carbogen breathing on chemoradiation and the effects of erythropoietin on transfusions. From March 1996 to April 2000, 42 (4 Stage III and 38 Stage IV) patients with head and neck cancer were treated with a twice-a-day hyperfractionated schedule. Each fraction consisted of 5 mg/m(2) of carboplatin plus 115 cGy with carbogen breathing. Treatment was given 5 days per week up to total doses of 350 mg/m(2) of carboplatin plus 8050 cGy in 7 weeks. Anemia was treated either by transfusion or by erythropoietin. Forty-one patients tolerated the treatment as scheduled. All patients tolerated the planned radiation dose. Five transfusions were given in the first group, but no transfusion was needed in the erythropoietin group. Local toxicities remained at the level expected with irradiation alone. Chemotherapy toxicity was moderate. Forty-two complete responses were achieved. At two years actuarial local control, cause-specific survival and overall survival are respectively 85%, 69%, and 68%. At four years estimated probabilities of local control, cause-specific survival and overall survival are also 85%, 69%, and 68%. These results compare favorably with those of most reported studies. The addition of carb...Continue Reading

References

Aug 1, 1979·International Journal of Radiation Oncology, Biology, Physics·F M Muggia, E Glatstein
Dec 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·H R Withers
Dec 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J C HoriotM Bolla
Jul 1, 1990·International Journal of Radiation Oncology, Biology, Physics·S Rockwell, J E Moulder
Nov 1, 1987·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·A VillarM Hernandez
Aug 1, 1987·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J S TobiasG Finn
May 1, 1984·International Journal of Radiation Oncology, Biology, Physics·J E Moulder, S Rockwell
Feb 1, 1995·International Journal of Radiation Oncology, Biology, Physics·A A Forastiere
Dec 1, 1994·International Journal of Radiation Oncology, Biology, Physics·A S GlicksmanH Wanebo
Dec 1, 1993·International Journal of Radiation Oncology, Biology, Physics·R S Lavey, W H Dempsey
May 1, 1993·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·L MartinM Guichard
May 1, 1997·International Journal of Radiation Oncology, Biology, Physics·D M BrizelM W Dewhirst
Oct 23, 1998·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J H KaandersA J van der Kogel
Feb 8, 2000·International Journal of Radiation Oncology, Biology, Physics·A BeckerJ Dunst

❮ Previous
Next ❯

Citations

Dec 17, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A ObermairA J Crandon
Dec 22, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C BokemeyerUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Philippe LambinMadelon Pijls-Johannesma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.